Pharma-Grade End-to-End

More than 14 Years of Excellence

Canndoc | GMP Pharma-Grade Cannabis

GMP Pharma-Grade Cannabis

The Highest Global Standard

Canndoc has been pioneering Pharma-Grade cannabis for more than 14 years. Over the years, Canndoc provided millions doses of to 40,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.

Driven by the mission of meeting patients’ needs and improving their quality of life, Canndoc holds product efficacy to be of paramount importance, delivering Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to achieve better patient health and treatment outcomes.


Company Presentation

At Our Core

Proficiency Through Experience
GMP Pharmaceutical Standards
Our products are held to the highest pharmaceutical standards, meeting global Good Manufacturing Practice (GMP) regulatory requirements.
Data Driven Research
Our proprietary patient use and experience database contains clinical information of 15,000 medical cannabis patients treated with more than 500,000 doses.
We are issuing ten clinical trials in IMC-GMP medical cannabis, collaborating with leading medical and academic research centres.
Clinical-Trial Focused
Global Player
We diversify and expand our global production and distribution capabilities through joint ventures and commercial agreements in Canada and Europe.
Proprietary Genetic Bank
Our proprietary genetic bank includes more than 30 unique cannabinoid profiles.
Proven Execution to Meet Demand
We’re scaling our production capacity and market penetration in order to provide GMP pharma-grade cannabis products to patients around the world.

Global Footprint

Positioned to Deliver

As governmental regulation spreads across the globe, more than 40 countries are adopting regulations that allow the use of cannabis for medical purposes. Our operations already encompass the entire value chain, from genetics, cultivation and production to sales and distribution, to meet the needs of pharma-grade cannabis for patients, doctors and pharmacies around the world.

Canndoc | GMP Pharma-Grade Cannabis

14+ years of product development

GMP Products Portfolio

We are bringing medical cannabis into the 21ˢᵗ century with pharma-grade treatments for patients. Our GMP standard products are prescribed for a range of indications including Neuropathic pain, Relief of pain of cancerous source, Inflammatory bowel disease, Post-traumatic stress disorder, Parkinson’s, Epileptic seizures and more.

Our products and genetics cover European, Canadian and Israeli regulatory requirements.

Canndoc | GMP Pharma-Grade Cannabis

Research & Development

Quality is our Priority

For more than 14 years our research has contributed to the advancement of medical cannabis through cutting-edge therapeutic development and building a portfolio of GMP products with efficacy as a top priority. We’re focused on validating our clinical significance through clinical trials with hospitals and universities.

Canndoc | GMP Pharma-Grade Cannabis

Clinical Trials

Dedicated to Patient Health

Based on our proprietary database of more than 40,000 patients and millions of doses, we initiated an array of clinical trials to validate the beneficial effect of our GMP pharma-grade cannabis on various indications: adult epilepsy, fibromyalgia, neuropathic pain, side effects of chemotherapy, parkinson, rheumatoid arthritis, radicular pain, PTSD, and lumbar radiculopathy.

Medical Partners

Advancing Patient Value, Together

Company News & Updates

Making Headlines
Show More >

Industry Experts  

Management Team
Nitsan Alon
Prior to joining Canndoc, Mr. Alon served as Major General in the Israel Defense Forces (IDF) where he accumulated over 35 years of operational experience in senior positions, including as the Head of the Israeli Operations Directorate and Central Command and Commander of the General Staff Elite Unit.
Ariel Romano
Mr. Romano is concurrently serving as InterCure’s Chief Financial Officer. Prior to joining Canndoc, Romano served as Financial Director of Asia-Pacific and Middle East at the NEC Corporation.
Roei Zerahia
Senior Executive Vice President
With multi sector experience, spanning entrepreneurship, business and academics, Mr. Zerahia is responsible for planning  and implementing CANNDOC's global and local business strategy.
Omri Nagdiman
VP Operations
Mr. Nagdiman brings over 15 years of global pharmaceutical experience in operations. Prior to joining Canndoc, Mr. Nagdiman served as a Senior Director of Global Operations Strategy at Teva pharmaceuticals. He holds an M.B.A. and B.Sc in Chemistry and Biology.
Meital Krupik (Adv.)
Deputy CEO, HR & Legal
With an extensive legal background, Krupik accumulated over 15 years of global managerial experience. Prior to Canndoc, Krupik served as Global COO at Pearl Cohen Zedek Latzer Baratz.
Iris Dolev
Executive Vice President Compliance
Prior to her current role, Mrs. Dolev has held several positions in Canndoc including the Vice President of Distribution. Mrs. Dolev  brings to Canndoc significant experience working with hospital staff and patients, and a profound understanding of the laws and regulations governing the pharmaceutical cannabis industry.
Tamar Avital Braurer
Israel Marketing Manager
With more than nine years of marketing and communications experience, Mrs. Avital Brauer joined Canndoc from Nestle IL, where she built some of Israel’s most popular food brands. She holds a B.A. in Political Science and an M.B.A.
Dany Reiss
Clinical Research Manager
Mr. Reiss Holds an M.A. in Management and a B.Sc. in Computational Biology from Bar-Ilan university. His experience includes over a decade of market research and competitive intelligence analysis from leading companies in Israel and abroad.
Dan Luski
BizDev Manager
Previous to Joining Canndoc, Mr. Luski’s experience includes more than 20 years of finance and wealth management with an extensive background in M&A and deal construction. He holds an MBA and a B.A. in finance
Omer Zerahia
Executive Vice President, Strategic Partnerships
With Cannabis industry experience spanning entrepreneurship, business and academics, Mr. Zerahia is charged with planning and implementing Canndoc’s global and local business strategy.
Board of Directors
Ehud Barak
Chairman of the Board
Ehud Barak, Chairman of the Board, is a former Israeli Prime Minister, Minister of Defense and Chief of Staff of the Israeli Defense Forces.
Mr. Barak has served as Canndoc’s board of Directors Chairman since March 2019. Prior his election as Prime Minister in 1999, Mr. Barak completed an illustrious 36 years career in the IDF as the most decorated soldier in its history. Mr. Barak has a B.Sc. in physics and Mathematics from the Hebrew University, Jerusalem and a M.Sc. degree in Economic-Engineering Systems from Stanford University, California. Mr. Barak currently serves on the board of Intercure Ltd. and two other Israeli companies: Carbyne Ltd., and Cybertoka Ltd.
Alon Granot
Mr. Granot has served on Canndoc’s Board of Directors since March 2019. From 2001 to 2018, Mr. Granot served as CFO and EVP at Frutarom Industries Ltd., leading M&A, business development and overall financial management until Frutarom was acquired for $7.1 billion in 2018. Mr. Granot holds a B.A. in economics and business management from the university of Haifa and an M.A. in Economics and Finance from the Technion.
Avner Neri Barak
Founder, President & Director
A global medical cannabis pioneer since 1984, Mr Barak founded Canndoc in 2008 and has since served as President and board member. Holding an Israeli license for medical cannabis production since 2008, Mr Barak has developed significant expertise extracting essential oils and extracts from a wide variety of medicinal plants and is considered a pioneer of Israel’s medical cannabis industry.
Alexander Rabinovich
A Board member since October 2018, Mr. Rabinovitch has significant experience with Nasdaq and TASE listed companies. Mr. Rabinovitch serve as CEO and director of G.F.C Green Fields Capital Ltd.,  a company listed on the Tel Aviv Stock Exchange and serves on the board of directors of XTL Biopharmaceuticals Ltd., a company listed on Nasdaq. Mr. Rabinovich holds a B.A. degree in economics and accounting from the University of Haifa.
לחצו לפרטים
Contact Us

We welcome questions regarding our company and product portfolio. You can reach us by filling out the contact form below or through email. For general medical information or medical condition-specific inquiries, please contact your healthcare provider.

#85 Medinat Hayehudim, Herzliya, Israel
Thank you!
Your submission has been received!
Something went wrong while submitting the form. Please try again or contact via Email.